Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

677
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
677
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The evolving role of cytokines for CAR-T cell manufacturing and beyond.

Nature biomedical engineering·2026
Same author

Transcriptional and functional profiling reveals unique activation of Adapter CAR T cells in acute myeloid leukemia.

Journal of translational medicine·2026
Same author

Selpercatinib as First-Line Therapy in a 9-Month-Old Infant With Metastatic <i>RET</i> Fusion-Positive Sarcoma: A Case Report.

JCO precision oncology·2026
Same author

Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort.

Journal for immunotherapy of cancer·2026
Same author

Noninvasive in vivo imaging of NF-κB activation predicts immunotherapy response in solid tumors.

Npj imaging·2026
Same author

Correction: Promiscuous class II-binding SARS-CoV-2-nuc derived vaccine-peptide induced extensive conventional, innate and unconventional T cell responses.

Frontiers in immunology·2026

Related Experiment Video

Updated: Sep 20, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

816

Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting.

Christian M Seitz1, Joerg Mittelstaet2, Daniel Atar1

  • 1Department of General Pediatrics, Hematology and Oncology, University Children's Hospital Tuebingen, Germany.

Oncoimmunology
|June 10, 2022
PubMed
Summary

The novel Adapter CAR (AdCAR) system enhances chimeric antigen receptor (CAR)-T cell therapy, offering controllable, flexible, and selective cancer targeting. This adaptable CAR-T technology overcomes limitations in current cancer treatments.

Keywords:
CAR-T cellImmunotherapyadapter CAR-T cell

More Related Videos

A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.6K
Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

15.2K

Related Experiment Videos

Last Updated: Sep 20, 2025

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

816
A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

16.6K
Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells
09:28

Quantitative High-throughput Single-cell Cytotoxicity Assay For T Cells

Published on: February 2, 2013

15.2K

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Chimeric antigen receptor (CAR)-T therapy shows promise for cancer treatment.
  • Current CAR-T limitations include restricted versatility, tractability, and lack of exclusive target antigens.
  • Need for enhanced control over CAR-T cell function is critical.

Purpose of the Study:

  • To engineer the Adapter CAR (AdCAR) system for temporal and qualitative control of CAR-T function.
  • To develop a versatile and adaptable CAR-T platform for cancer therapy.

Main Methods:

  • Engineered the Adapter CAR (AdCAR) system utilizing a Linker-Label-Epitope structure.
  • Redirected AdCAR-T cells to target surface antigens via biotin-labeled adapter molecules.
  • Evaluated AdCAR-T efficacy and specificity in preclinical mouse models.

Main Results:

  • AdCAR-T cells demonstrated highly specific and controllable effector functions against multiple target antigens.
  • AdCAR-T therapy durably eliminated aggressive lymphoma in mouse models.
  • The system showed potential for preventing antigen escape through combinatorial targeting and differential lysis based on multiplex antigen profiles.

Conclusions:

  • The AdCAR technology provides controllable, flexible, combinatorial, and selective targeting capabilities for CAR-T cell therapy.
  • AdCAR-T offers a promising strategy to overcome limitations of current CAR-T approaches.
  • This adaptable platform has the potential to broaden the applicability of CAR-T cell therapies in oncology.